Furthermore, we propose that pharmacologically targeting WNT/β-catenin signaling by MNK1 inhibitors may have prophylactic or therapeutic potential specifically in (oligodendro)glioma patients harboring CDH1 variants affecting this pathway. The gene discussed is CDH1; the disease is central nervous system cancer.